Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IMRA - Imara Inc

Close
23.75
-0.250   -1.053%

Share volume: 0
Last Updated: Fri 24 Feb 2023 10:00:00 PM CET
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%
$24.00
-0.25
-1.04%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 50%
Dept financing 1%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.19%
1 Month
26.14%
3 Months
14.60%
6 Months
353.45%
1 Year
267.83%
2 Year
-59.60%
Key data
Stock price
$23.75
P/E Ratio 
0.00
DAY RANGE
N/A - $23.75
EPS 
$0.00
52 WEEK RANGE
$0.97 - $5.59
52 WEEK CHANGE
$2.68
MARKET CAP 
137.990 M
YIELD 
N/A
SHARES OUTSTANDING 
26.234 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$100,863
AVERAGE 30 VOLUME 
$79,205
Company detail
CEO:
Region: US
Website: imaratx.com
Employees: 41
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.

Recent news